Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have...

When Psychedelic Experiences Turn into Crisis, Training Can Make All the...

Weekly Psychedelic Policy Briefing: September 30th, 2026

Quarterly Psychedelics Briefing: Q3 2026

Weekly Psychedelic Policy Briefing, September 21, 2026

Load more

EDITOR PICKS

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

Weekly Psychedelic Policy Briefing: October 12, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©